| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of... |
| 08 Sep 2026 |
8-K: Results of Operations and Financial Condition
Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 |
| 11 Aug 2026 |
8-K: Other Events
Non-Viral Genetic Medicine Virtual KOL Event: Emerging NMIBC Market Insights August 11, 2026 |
| 17 Jul 2026 |
8-K: Regulation FD Disclosure
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of... |
| 16 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 |
| 15 Jun 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +3 more
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual General Meeting of shareholders (the “Annual Meeting”) of enGene Therapeutics Inc. (the “Company”) was held on June 9, 2026 at 8:30 a.m. EDT. A total of 56,196,302 common shares of the Company, no par value (the “Common S... |
| 07 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
54% complete response (CR) rate at any time; 43% six-month CR rate |
| 09 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
The Articles of the Company have been altered to reflect the change of the Company’s name from “enGene Holdings Inc.” to “enGene Therapeutics Inc.”, pursuant to a resolution adopted by the Company’s board of directors at a meeting held M... |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
enGene Holdings Inc., a company existing under the laws of the Province of British Columbia (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
LEGEND pivotal cohort update planned for a spring 2026 medical conference |
| 21 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This Second Amendment to amended and restated Loan and Security Agreement (this “Amendment”) is dated as of January 20, 2026 and is entered into by and between enGene Holdings Inc., a public corporation continued under the laws of Britis... |
| 21 Jan 2026 |
8-K: Regulation FD Disclosure
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. |
| 22 Dec 2025 |
8-K: Results of Operations and Financial Condition
Completed enrollment in LEGEND’s pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ |
| 14 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
enGene Holdings Inc., a company existing under the laws of the Province of British Columbia (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 12,558,823 c... |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of... |
| 02 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 2, 2025, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), upon recommendation from the Compensation Committee of the Board, approved an amendment (the “Amendment”) to the Employment Agreement, date... |
| 30 Sep 2025 |
8-K: Regulation FD Disclosure
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy |
| 11 Sep 2025 |
8-K: Results of Operations and Financial Condition
Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achieved |
Loading...